Analyst Price Targets — GNLX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 21, 2025 5:07 pm | — | Maxim Group | $20.00 | $6.67 | TheFly | Genelux price target raised to $20 from $10 at Maxim |
| October 21, 2025 11:55 am | Chad Messer | Lake Street | $16.00 | $6.35 | TheFly | Genelux initiated with a Buy at Lake Street |
| October 21, 2025 11:52 am | Chad Messer | Loop Capital Markets | $16.00 | $6.35 | StreetInsider | Lake Street Capital Markets Starts Genelux Corp. (GNLX) at Buy |
Latest News for GNLX
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026; expected to fund operations into 1Q27 -- WESTLAKE VILLAGE, Calif., May 07, 2026 (GLOBE…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GNLX.
U.S. House Trading
No House trades found for GNLX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.